Health
ACC 2021: J&J, Bayer pad case for Xarelto in post-surgery artery disease patients – FiercePharma
Bayer and J&J last year showed their legacy blood thinner Xarelto could help post-surgery patients in tough-to-treat artery disease. Now, the partners have data…
With an approval filing already on the FDAs docket, Bayer and Johnson & Johnson are padding their case for launching legacy blood thinner Xarelto in artery disease patients after surgery.
In long-term data from its pivotal trial in peripheral artery disease, Xarelto plus aspirin cut the risk of a variety of clot-related episodesacute clots in the limbs, a major amputation for vascular reasons, heart attack, stroke or cardiovascular deathby 14% compared with aspirin alone in patients who’d had surgery…
-
Noosa News24 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News22 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
Noosa News22 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
General20 hours agoDairy farmers devastated by floods across parts of New South Wales